Endomorphins: Potential roles and therapeutic indications in the development of opioid peptide analgesic drugs

Medicinal Research Reviews

Volumn 32, Issue 3, 2012, Pages 536-580

  Liu, Wei X ^a   Wang, Rui ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Analgesic drugs; Bioavailability; Blood brain barrier; Endomorphins; Structure activity relationships

Indexed keywords

AMINO ACID; ENDORPHIN; GLYCOPEPTIDE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; PEPTIDOMIMETIC AGENT;

AMINO ACID SUBSTITUTION; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CONFORMATION; CYCLIZATION; DRUG CONFORMATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ENZYME STABILITY; GLYCOSYLATION; HUMAN; LIPOPHILICITY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANALGESICS; ANIMALS; BLOOD-BRAIN BARRIER; DRUG DESIGN; DRUG TOLERANCE; GLYCOSYLATION; GUINEA PIGS; LIPIDS; OLIGOPEPTIDES; OPIOID PEPTIDES; PEPTIDES, CYCLIC; PEPTIDOMIMETICS; RATS;

EID: 84860339691     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20222     Document Type: Article

References (179)

1. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the μ-opioid receptor. Nature 1997;386:499-502.
2. Hackler L, Zadina JE, Ge LJ, Kastin AJ. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 1997;18:1635-1639.
3. Stone LS, Fairbanks CA, Laughlin TM, Nguyen HO, Bushy TM, Wessendorf MW, Wilcox GL. Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport 1997;8:3131-3135.
4. Yamaguchi T, Kitagawa K, Kuraishi Y. Itch-associated response and antinociception induced by intracisternal endomorphins in mice. Jph J Pharmacol 1998;78:337-343.
5. Przewlocka B, Mika J, Labuz D, Tóth G, Przewlocki R. Spinal analgesic action of endomorphins in acute, inflammatory and neuropathic pain in rats. Eur J Pharmacol 1999;367:189-196.
6. Tseng LF, Narita M, Suganuma C, Mizoguchi H, Ohsawa M, Nagase H, Kampine JP. Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 2000;292:576-583.
7. Przewlocki R, Labuz D, Mika J, Przewlocka B, Tömböly C, Tóth G. Pain inhibition by endomorphins. Ann N Y Acad Sci 1999;897:154-164.
8. Wilson AM, Soignier RD, Zadina JE, Kastin AJ, Nores WL, Olson RD, Olson GA. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides 2000;21:1871-1874.
9. Czapla MA, Gozal D, Alea OA, Beckerman RC, Zadina JE. Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine. Am J Respir Crit Care Med 2000;162:994-999.
10. Tömböly C, Péter A, Tóth G. In vitro quantitative study of the degradation of endomorphins. Peptides 2002;23:1573-1580.
11. Reisine T, Bell GI. Molecular biology of opioid receptors. Trends Neurosci 1993;16:506-510.
12. Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat κ opioid receptor reveals sequence similarities to the μ and δ opioid receptors. Biochem J 1993;295:625-628.
13. Schwyzer R. Molecular mechanism of opioid receptor selection. Biochemistry 1986;25:6335-6342.
14. Schwyzer R. 100 years lock-and key concept: Are peptides keys shaped and guided to their receptors by the target cell membrane? Biopolymers (Peptide Sci) 1995;37:5-16.
15. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992;89:12048-12052.
16. Evans CJ, Keith DE, Morrison H, Magendzo K, Edwards RH. Cloning of a δ opioid receptor by functional expression. Science 1992;258:1952-1955.
17. Fukuda K, Kato S, Mori K, Nishi M, Takeshima H. Primary structures and expression from cDNAs of rat opioid receptor δ- and μ-subtypes. FEBS Lett 1993;327:311-314.
18. Chen Y, Mesick A, Liu J, Hurley A, Yu L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol Pharmacol 1993;44:8-12.
19. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, Bell GI. Cloning and functional comparison of κ and δ opioid receptors from mouse brain. Proc Natl Acad Sci USA 1993;90:6736-6740.
20. Minami M, Toya T, Katao Y, Maekawa K, Nakamura S, Onogi T, Kaneko S, Satoh M. Cloning and expression of a cDNA for the rat k-opioid receptor. FEBS Lett 1993;329:291-295.
21. Podlogar BL, Paterlini MG, Ferguson DM, Leo GC, Demeter DA, Brown FK, Reitz AB. Conformational analysis of the endogenous μ-opioid agonist endomorphin-1 using NMR spectroscopy and molecular modeling. FEBS Lett 1998;439:13-20.
22. Law PY, Wong YH, Loh HH. Mutational analysis of the structure and function of opioid receptors. Biopolymers (Peptide Sci) 1999;51:440-455.
23. Yang YR, Chiu TH, Chen CL. Structure-activity relationships of naturally occurring and synthetic opioid tetrapeptides acting on locus coeruleus neurons. Eur J Pharmacol 1999;372:229-236.
24. Hruby VJ, Balse PM. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr Med Chem 2000;7:945-970.
25. Janecka A, Fichna J, Janecki T. Opioid receptors and their ligands. Curr Top Med Chem 2004;4:1-17.
26. Gentilucci L. New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr Top Med Chem 2004;4:19-38.
27. Janecka A, Kruszynski R. Conformationally restricted peptides as tools in opioid receptor studies. Curr Med Chem 2005;12:471-481.
28. Cardillo G, Gentilucci L, Tolomelli A. Unusual amino acids: Synthesis and introduction into naturally occurring peptides and biologically active analogues. Mini-Rev Med Chem 2006;6:293-304.
29. Janecka A, Staniszewska R, Fichna J. Endomorphin analogs. Curr Med Chem 2007;14:3201-3208.
30. Schiller PW. Bi- or multifunctional opioid peptide drugs. Life Sci 2010;86:598-603.
31. Paterlini MG, Avitabile F, Ostrowski BG, Ferguson DM, Portoghese PS. Stereochemical requirements for receptor recognition of the ì-opioid peptide endomorphin-1. Biophys J 2000;78:590-599.
32. 2, and examination of their opioid receptor binding activities and solution conformation. Biochem Biophys Res Commun 2000;276:7-11.
33. Cardillo G, Gentilucci L, Melchiorre P, Spampinato S. Synthesis and binding activity of endomorphin-1 analogues containing β-amino acids. Bioorg Med Chem Lett 2000;10:2755-2758.
34. Keller M, Boissard C, Patiny L, Chung NN, Lemieux C, Mutter M, Schiller PW. Pseudoproline-containing analogues of morphiceptin and endomorphin-2: Evidence for a cis Tyr-Pro amide bond in the bioactive conformation. J Med Chem 2001;44:3896-3903.
35. Doi M, Asano A, Komura E, Ueda Y. The structure of an endomorphin analogue incorporating 1-aminocyclohexane-1-carboxylic acid for proline is similar to the β-turn of Leu-enkephalin. Biochem Biophys Res Commun 2002;297:138-142.
36. Tóth G, Keresztes A, Tömböly C, Péter A, Fülöp F, Tourwé D, Navratilova é, Varga E, Roeske WR, Yamamura HI, Szucs M, Borsodi A. New endomorphin analogs with μ-agonist and δ-antagonist properties. Pure Appl Chem 2004;76:951-957.
37. Keresztes A, Szucs M, Borics A, Kövér KE, Forró E, Fülöp F, Tömböly C, Péter A, Páhi A, Fábián G, Murányi M, Tóth G. New endomorphin analogues containing alicyclic β-amino acids: influence on bioactive conformation and pharmacological profile. J Med Chem 2008;51:4270-4279.
38. Biondi B, Giannini E, Negri L, Melchiorri P, Lattanzi R, Rosso F, Ciocca L, Rocchi R. Opioid peptides: Synthesis and biological activity of new endomorphin analogues. Int J Pept Res Ther 2006;12:145-151.
39. Shi ZH, Wei YY, Wang CJ, Yu L. Synthesis and analgesic activities of endomorphin-2 and its analogues. Chem Biodivers 2007;4:458-467.
40. Staniszewska R, Fichna J, Gach K, Tóth G, Poels J, Broeck JV, Janecka A. Synthesis and biological activity of endomorphin-2 analogs incorporating piperidine-2-, 3- or 4-carboxylic acids instead of proline in position 2. Chem Biol Drug Des 2008;72:91-94.
41. 1]endomorphin analogs with six-membered proline surrogates in position 2. Bioorg Med Chem 2009;17:3789-3794.
42. 2 residue. Bioorg Med Chem Lett 2009;19:4115-4118.
43. Perlikowska R, Fichna J, Wyrebska A, Poels J, Broeck JV, Tóth G, Storr M, do-Rego JC, Janecka A. Design, synthesis and pharmacological characterization of endomorphin analogues with non-cyclic amino acid residues in position 2. Basic Clin Pharmacol Toxicol 2009;106:106-113.
44. Hruby VJ, Gehrig CA. Recent developments in the design of receptor specific opioid peptides. Med Res Rev 1989;9:343-401.
45. Olma A, Tourwé D. Synthesis and binding properties of endomorphin-2 analogs containing α-hydroxymethyl amino acids. Lett Pept Sci 2000;7:93-96.
46. Cardillo G, Gentilucci L, Qasem AR, Sgarzi F, Spampinato S. Endomorphin-1 analogues containing β-proline are μ-opioid receptor agonists and display enhanced enzymatic hydrolysis resistance. J Med Chem 2002;45:2571-2578.
47. Sasaki Y, Sasaki A, Niizuma H, Goto H, Ambo A. Endomorphin 2 analogues containing Dmp residue as an aromatic amino acid surrogate with high μ-opioid receptor affinity and selectivity. Bioorg Med Chem 2003;11:675-678.
48. Sperlinga E, Kosson P, Urbanczyk-Liplowska Z, Ronsisvalle G, Carr DB, Lipkowski AW. 6-Hydroxy-1, 2, 3, 4-tetrahydro-isoquinoline-3-carboxylic acid mimics active conformation of tyrosine in opioid peptides. Bioorg Med Chem Lett 2005;15:2467-2469.
49. Dolle RE, Machaut M, Martinez-Teipel B, Belanger S, Cassel JA, Stabley GJ, Graczyk TM, DeHaven RN. (4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands. Bioorg Med Chem Lett 2004;14:3545-3548.
50. Cardillo G, Gentilucci L, Tolomelli A, Calienni M, Qasem AR, Spampinato S, Calienni M. Stability against enzymatic hydrolysis of endomorphin-1 analogues containing β-proline. Org Biomol Chem 2003;1:1498-1502.
51. Eguchi M, Shen RYW, Shea JP, Lee MS, Kahn M. Design, synthesis, and evaluation of opioid analogues with non-peptidic β-turn scaffold: Enkephalin and endomorphin mimetics. J Med Chem 2002;45:1395-1398.
52. Cardillo G, Gentilucci L, Tolomelli A, Spinosa R, Calienni M, Qasem AR, Spampinato S. Synthesis and evaluation of the affinity toward μ-opioid receptors of atypical, lipophilic ligands based on the sequence c[-Tyr-Pro-Trp-Phe-Gly-]. J Med Chem 2004;47:5198-5203.
53. Gentilucci L, Squassabia F, Demarco R, Artali R, Cardillo G, Tolomelli A, Spampinato S, Bedini A. Investigation of the interaction between the atypical agonist c[YpwFG] and MOR. FEBS J 2008;275:2315-2337.
54. Janecka A, Fichna J, Kruszynski R, Sasaki Y, Ambo A, Costentin J, do-Rego JC. Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs. Biochem Pharmacol 2005;71:188-195.
55. Perlikowska R, do-Rego JC, Cravezic A, Fichna J, Wyrebska A, Tóth G, Janecka A. Synthesis and biological evaluation of cyclic endomorphin-2 analogs. Peptides 2010;31:339-345.
56. Lu Y, Weltrowska G, Lemieux C, Chung NN, Schiller PW. Stereospecific synthesis of (2S)-2-methyl-3-(2', 6'-dimethyl-4'-hydroxyphenyl)-propionic acid (Mdp) and its incorporation into an opioid peptide. Bioorg Med Chem Lett 2001;11:323-325.
57. 2 analogues lacking an N-terminal amino group: Potent and selective κ-opioid antagonists. J Med Chem 2001;44:3048-3053.
58. Okada Y, Fujita Y, Motoyama T, Tsuda Y, Yokoi T, Li T, Sasaki Y, Ambo A, Jinsmma Y, Bryant SD, Lazarus LH. Structural studies of [2', 6'-dimethyl-L-tyrosine1]endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond. Bioorg Med Chem Lett 2003;11:1983-1994.
59. Li T, Fujita Y, Tsuda Y, Miyazaki A, Ambo A, Sasaki Y, Jinsmaa Y, Bryant SD, Lazarus LH, Okada Y. Development of potent μ-opioid receptor ligands using unique tyrosine analogues of endomorphin-2. J Med Chem 2005;48:586-592.
60. 1]endomorphin-2-mediated antinociception in the mouse. Eur J Pharmacol 2005;509:37-42.
61. Fujita Y, Tsuda Y, Li T, Motoyama T, Takahashi M, Shimizu Y, Yokoi Y, Sasaki Y, Ambo A, Kita A, Jinsmaa Y, Bryant SD, Lazarus LH, Okada Y. Development of potent bifunctional endomorphin-2 analogues with mixed μ-/δ-opioid agonist and δ-opioid antagonist properties. J Med Chem 2004;47:3591-3599.
62. Bryant SD, Jinsmaa Y, Salvadori S, Okada Y, Lazarus LH. Dmt and opioid peptides: A potent alliance. Biopolymers (Pept Sci) 2003;71:86-102.
63. Gentilucci L, Tolomelli A. Recent advances in the investigation of the bioactive conformation of peptides active at the μ-opioid receptor. Conformational analysis of endomorphins. Curr Top Med Chem 2004;4:105-121.
64. Choi H, Murray TF, Aldrich JV. Synthesis and evaluation of potential affinity labels derived from endomorphin-2. J Pept Res 2003;61:58-62.
65. Tömböly C, Kövér KE, Péter A, Tourwé D, Biyashev D, Benyhe S, Borsodi A, Al-Khrasani M, Rónai AZ, Tóth G. Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues. J Med Chem 2004;47:735-743.
66. Gao YF, Liu X, Liu WX, Qi YM, Liu XF, Zhou YF, Wang R. Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3 or 4. Bioorg Med Chem Lett 2006;16:3688-3692.
67. Fichna J, do-Rego JC, Kosson P, Costentinc J, Janecka A. Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position. Biochem Pharmacol 2005;69:179-185.
68. Kruszynski R, Fichna J, do-Rego JC, Janecki T, Kosson P, Pakulska W, Costentin J, Janecka A. Synthesis and biological activity of N-methylated analogs of endomorphin-2. Bioorg Med Chem 2005;13:6713-6717.
69. Lengyel I, Orosz G, Biyashev D, Kocsis L, Al-Khrasani M, Rónai A, Tömböly C, Fürst Z, Tóth G, Borsodi A. Side chain modifications change the binding and agonist properties of endomorphin 2. Biochem Biophy Res Commun 2002;290:153-161.
70. Li T, Shiotani K, Miyazaki A, Tsuda Y, Ambo A, Sasaki Y, Jinsmaa Y, Marczak E, Bryant SD, Lazarus LH, Okada Y. Bifunctional [2', 6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed μ-agonist/δ-antagonist and dual μ-agonist/δ-agonist opioid ligands. J Med Chem 2007;50:2753-2766.
71. Honda T, Shirasu N, Isozaki K, Kawano W, Shigehiro D, Chung Y, Fujita Y, Nose T, Shimohigashi Y. Differential receptor binding characteristics of consecutive phenylalanines in μ-opioid specific peptide ligand endomorphin-2. Bioorg Med Chem 2007;15:3883-3888.
72. Paterlini MG, Avitabile F, Ostrowski BG, Ferguson DM, Portoghese PS. Stereochemical requirements for receptor recognition of the μ-opioid peptide endomorphin-1. Biophys J 2000;78:590-599.
73. Al-Khrasani M, Orosz G, Kocsis L, Farkas V, Magyar A, Lengyel I, Benyhe S, Borsodi A, Rónai A. Receptor constants for endomorphin-1 and endomorphin-1-ol indicate differences in efficacy and receptor occupancy. Eur J Pharmacol 2001;421:61-67.
74. 1H NMR spectroscopy and molecular modeling calculation. J Pept Res 2001;58:399-412.
75. Wang CL, Yao JL, Yu Y, Shao X, Cui Y, Liu HM, Lai LH, Wang R. Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem 2008;16:6415-6422.
76. Vázquez ME, Blanco JB, Salvadori S, Trapella C, Argazzi R, Bryant SD, Jinsmaa Y, Lazarus LH, Negri L, Giannini E, Lattanzi R, Colucci M, Balboni G. 6-N, N-Dimethylamino-2, 3-naphthalimide: A new environment-sensitive fluorescent probe in δ- and μ-selective opioid peptides. J Med Chem 2006;49:3653-3658.
77. Yu Y, Shao X, Cui Y, Liu HM, Wang CL, Fan LZ, Liu J, Dong SL, Cui YX, Wang R. Structure-activity study on the spatial arrangement of the third aromatic ring of endomorphins 1 and 2 using an atypical constrained C terminus. Chem Med Chem 2007;2:309-317.
78. Podlogar BL, Paterlini MG, Ferguson DM, Leo GC, Demeter DA, Brown FK, Reitz AB. Conformational analysis of the endogenous μ-opioid agonist endomorphin-1 using NMR spectroscopy and molecular modeling. FEBS Lett 1998;439:13-20.
79. Harrison BA, Gierasch MT, Neilan C, Pasternak GW, Verdine GL. High-affinity mu opioid receptor ligands discovered by the screening of an exhaustively stereodiversified library of 1, 5-enediols. J Am Chem Soc 2002;124:13352-13353.
80. Shi ZJ, Harrison BA, Verdine GL. Unpredictable stereochemical preferences for mu opioid receptor activity in an exhaustively stereodiversified library of 1, 4-enediols. Org Lett 2003;5:633-636.
81. Harrison BA, Pasternak GW, Verdine GL. 2, 6-Dimethyltyrosine analogues of a stereodiversified ligand library: Highly potent, selective, non-peptidic μ opioid receptor agonists. J Med Chem 2003;46:677-680.
82. Wei J, Shao X, Gong MZ, Zhu BB, Cui YX, Gao YF, Wang R. Structure-activity relationships of novel endomorphin-2 analogues with N-O turns induced by a-aminoxy acids. Bioorg Med Chem Lett 2005;15:2986-2989.
83. 2, display partial agonist potency but significant antinociception. Life Sci 2005;77:1155-1165.
84. Gao YF, Liu X, Wei J, Zhu BB, Chen Q, Wang R. Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett 2005;15:1847-1850.
85. Tömböly C, Ballet S, Feytens D, Kövér KE, Borics A, Lovas S, Al-Khrasani M, Fürst Z, Tóth G, Benyhe S, Tourwé D. Endomorphin-2 with a β-turn backbone constraint retains the potent μ-opioid receptor agonist properties. J Med Chem 2008;51:173-177.
86. Mentlein R. Dipeptidyl-peptidase IV (CD26): Role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.
87. Goldberg IE, Rossi GC, Letchworth SR, Mathis JP, Ryan-Moro J, Leventhal L, Su W, Emmel D, Bolan EA, Pasternak GW. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 1998;286:1007-1013.
88. Horvath G, Szikszay M, Tömböly C, Benedek G. Antinociceptive effects of intrathecal endomorphin-1 and -2 in rats. Life Sci 1999;65:2635-2641.
89. Mizoguchi H, Narita M, Oji DE, Suganuma C, Nagase H, Sora I, Uhl GR, Cheng EY, Tseng LF. The μ-opioid receptor gene dose-dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in μ-opioid receptor knockout mice. Neuroscience 1999;94:203-207.
90. Soignier RD, Vaccarino AL, Brennan AM, Kastin AJ, Zadina JE. Analgesic effects of endomorphin-1 and endomorphin-2 in the formalin test in mice. Life Sci 2000;67:907-912.
91. Wang YQ, Zhu CB, Wu GC, Cao XD, Wang Y, Cui DF. Effects of orphanin FQ on endomorphin-1 induced analgesia. Brain Res 1999;835:241-246.
92. Harbeck HT, Mentlein R. Aminopeptidase P from rat brain: Purification and action on bioactive peptides. Eur J Biochem 1991;198:451-458.
93. Péter A, Tóth G, Tömböly C, Gentilucci L, Tourwe D. Liquid chromatographic study of the enzymatic degradation of endomorphins, with identification by electrospray ionization mass spectrometry. J Chromatogr A 1999;846:39-48.
94. Tömböly C, Péter A, Tóth G. In vitro quantitative study of the degradation of endomorphins. Peptides 2002;23:1573-1580.
95. Janecka A, Staniszewska R, Gach K, Fichna J. Enzymatic degradation of endomorphins. Peptides 2008;29:2066-2073.
96. Shane R, Wilk S, Bodnar RJ. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 1999;815:278-286.
97. Okada Y, Tsuda Y, Bryant SD, Lazarus LH. Endomorphins and related opioid peptides. Vita Horm 2002;65:257-279.
98. 2]endomorphin 2 (TAPP) are mediated by an L-NAME-sensitive mechanism in the rat. J Cardiovasc Pharmacol 1999;33:280-284.
99. 2 discriminate different μ-opioid receptor mediated antinociception in mice. Br J Pharmacol 2002;137:1143-1146.
100. Spampinato S, Qasem AR, Calienni M, Murari G, Gentilucci L, Tolomelli A, Cardillo G. Antinociception by a peripherally administered novel endomorphin-1 analogue containing β-proline. Eur J Pharmacol 2003;469:89-95.
101. Chang KJ, Wei ET, Killian A, Chang JK. Potent morphiceptm analogs: Structure activity relationships and morphine-like activities. J Pharmacol Exp Ther 1983;227:403-408.
102. Kosterlitz HW, Lord JAH, Paterson SJ, Waterfield AA. Effects of changes in the structure of enkephalins and of narcotic analgesic drugs in their interactions with μ and δ-receptors. Br J Pharmacol 1980;68:333-342.
103. Mark JE, Goodman M. Conformational aspects of polypeptides. XXIV. Conformational energies of poly-N-methyl-L-alanine chains. Biopolymers 1967;5:809-814.
104. Janecka A, Kruszynski R, Fichna J, Kosson P, Janecki T. Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids. Peptides 2006;27:131-135.
105. Hruby VJ, Balse PM. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr Med Chem 2000;7:945-970.
106. Borchardt RT. Optimizing oral absorption of peptides using prodrug strategies. J Contr Rel 1999;62:231-238.
107. Gudmundsson OS, Jois SD, Vander-Velde DG, Siahaan TJ, Wang B, Borchardt RT. The effect of conformation on the membrane permeation of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides. J Pept Res 1999;53:383-392.
108. Knipp GT, Vander-Velde DG, Siahaan TJ, Borchardt RT. The effect of β-turn structure on the passive diffusion of peptides across Caco-2 cell monolayers. Pharm Res 1997;14:1332-1340.
109. Wang B, Nimkar K, Wang W, Zhang H, Shan D, Gudmundsson O, Gangwar S, Siahaan TJ, Borchardt RT. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers. J Pept Res 1999;53:370-382.
110. Schiller PW. Development of opioid peptide analogs as pharmacologic tools and as potential drugs: Current status and future directions. NIDA Res Monogr 1991;112:180-197.
111. Schiller PW. Development of receptor-selective opioid peptide analogs as pharmacologic tools and as potential drugs. Handb Exp Pharmacol 1993;104:681-710.
112. Hruby VJ, Agnes RS. Conformation-activity relationships of opioid peptides with selective activities at opioid receptors. Biopolymers 1999;51:391-410.
113. 5]enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J Pharmacol Exp Ther 1992;263:1308-1316.
114. 2]enkephalin and two halogenated analogs after intravenous administration. J Pharmacol Exp Ther 1991;259:1109-1117.
115. Goodman M, Zapf C, Rew Y. New reagents, reactions, and peptidomimetics for drug design. Biopolymers 2001;60:229-245.
116. Rew Y, Malkmus S, Svensson C, Yaksh TL, Chung NN, Schiller PW, Cassel JA, DeHaven RN, Goodman M. Synthesis and biological activities of cyclic lanthionine enkephalin analogues: δ-Opioid receptor selective ligands. J Med Chem 2002;45:3746-3754.
117. Schiller PW, Nguyen TMD, Lemieux C, Maziak LA. A novel side-chain-linked antiparallel cyclic dimer of enkephalin. FEBS Lett 1985;191:231-234.
118. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969;40:648-677.
119. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999;22:11-28.
120. Kneisel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 2000;20:57-76.
121. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000;89:1371-1388.
122. Habgood MD, Begley DJ, Abbott NJ. Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol 2000;20:231-253.
123. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 2001;22:2329-2343.
124. Ganapathy V, Miyauchi S. Transport systems for opioid peptides in mammalian tissues. AAPS J 2005;7:852-856.
125. Witt KA, Davis TP. CNS drug delivery: Opioid peptides and the blood-brain barrier. AAPS J 2006;8:76-88.
126. Dhanasekaran M, Polt R. New prospects for glycopeptide based analgesia: Glycoside-induced penetration of the blood-brain barrier. Curr Drug Deliv 2005;2:59-73.
127. Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Curr Top Med Chem 2009;9:182-196.
128. Pardridge WM, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain bariier. Proc Natl Acad Sci USA 1995;92:5592-5596.
129. Vehaskari VM, Chang CT, Stevens JK, Robson AM. The effects of polycations on vascular permeability in the rat. A proposed role for charge sites. J Clin Invest 1984;73:1053-1061.
130. Hardebo JE, Kahrstrom J. Endothelial negative surface charge areas and blood-brain barrier function. J Acta Physiol Scand 1985;125:495-499.
131. Hau VS, Huber JD, Campos CR, Lipkowski AW, Misicka A, Davis T. Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II. J Pharm Sci 2002;91:2140-2149.
132. Liu HM, Liu XF, Yao JL, Wang CL, Yu Y, Wang R. Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1. J Pharmacol Exp Ther 2006;319:308-316.
133. Egleton RD, Mitchell SA, Huber JD, Janders J, Stropova D, Polt R, Yamamura HI, Hruby VJ, Davis TP. Improved bioavailability to the brain of glycosylated met-enkephalin analogs. Brain Res 2000;881:37-46.
134. Fisher JF, Harrison AW, Bundy GL, Wilkinson KF, Rush BD, Ruwart MJ. Peptide to glycopeptide: Glycosylated oligopeptide renin inhibitors with attenuated in vivo clearance properties. J Med Chem 1991;34:3140-3143.
135. Powell MF, Stewart T, Otvos L, Urge L, Gaeta FC, Sette A, Arrhenius T, Thomson D, Soda K, Colon SM. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm Res 1993;10:1268-1273.
136. Polt R, Porreca F, Szabo LZ, Bilsky EJ, Davis P, Abbruscato TJ, Davis TP, Horvath R, Yamamura HI, Hruby VJ. Glycopeptide enkephalin analogues produce analgesia in mice: Evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci USA 1994;91:7114-7118.
137. Negri L, Lattanzi R, Tabacco F, Orrú L, Severini C, Scolaro B, Rocchi R. Dermorphin and deltorphin glycosylated analogues: Synthesis and antinociceptive activity after systemic administration. J Med Chem 1999;42:400-404.
138. Buskas T, Ingale S, Boons GJ. Glycopeptides as versatile tools for glycobiology. Glycobiology 2006;16:113R-136R.
139. Horvat S. Opioid peptides and their glycoconjugates: Structure-activity relationships. Curr Med Chem 2001;1:133-154.
140. Bardají E, Torres JL, Clapés P, Albericio F, Barany G, Rodríguez RE, Sacristán MP, Valencia G. Synthesis and biological activity of O-glycosylated morphiceptin analogues. J Chem Soc Perkin Trans 1991;1:1755-1759.
141. Barbara B, Giannini E, Negri L, Melchiorri P, Lattanzi R, Rosso F, Ciocca L, Rocchi R. Opioid peptides: Synthesis and biological activity of new endomorphin analogues. Int J Pept Res Ther 2006;12:145-151.
142. Koda Y, Borgo MD, Wessling ST, Lazarus LH, Okada Y, Totha I, Blanchfield JT. Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem 2008;16:6286-6296.
143. Palian MM, Boguslavsky VI, O'Brien DF, Polt R. Glycopeptide-membrane interactions: Glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media. J Am Chem Soc 2003;125:5823-5831.
144. Koda Y, Liang MT, Blanchfield JT, Toth I. In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue. Int J Pharm 2008;356:37-43.
145. Horner KA, Zadina JE. Internalization and down-regulation of μ opioid receptors by endomorphins and morphine in SH-SY5Y human neuroblastoma cells. Brain Res 2004;1028:121-132.
146. Nestler EJ, Hope BJ, Widnell KL. Drug addiction: A model for the molecular basis of neural plasticity. Neuron 1993;11:995-1006.
147. Taylor DA, Fleming WW. Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. J Pharmacol Exp Ther 2001;297:11-18.
148. Borgland SL. Acute opioid receptor desensitization and tolerance: Is there a link? Clin Exp Pharmacol Physiol 2001;28:147-154.
149. Harrison LM, Kastin AJ, Zadina JE. Opiate tolerance and dependence: Receptors, G-proteins, and antiopiates. Peptides 1998;19:1603-1630.
150. 2-adrenergic receptors between the plasma membrane and endosomes containing transferring receptors. J Biol Chem 1992;267:3530-3538.
151. Yu SS, Lefkowitz RJ, Hausdorff WP. β-Adrenergic receptor sequestration. A potential mechanism of receptor resensitization. J Biol Chem 1993;268:337-341.
152. Puehler W, Zollner C, Shaqura MA, Krause H, Schafer M, Stein C. Rapid upregulation of μ opioid receptor mrna in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction. Neurosci 2004;129:473-479.
153. Hong EJ, Rice KC, Calderon S, Woods JH, Traynor JR. Convulsive behavior of nonpeptide δ-opioid ligands: Comparison of SNC80 and BW373U86 in mice. Analgesia 1998;3:269-276.
154. 2 opioid receptors in the development of morphine dependence in mice. J Pharmacol Exp Ther 1993;264:1141-1145.
155. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockage of δ opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 1991;258:299-303.
156. Miyamoto Y, Brown WD, Portoghese PS, Takemori AE. Lack of involvement of δ-1 opioid receptors in the development of physical dependence on morphine in mice. J Pharmacol Exp Ther 1994;270:37-39.
157. Fundytus ME, Schiller PW, Shapiro M, Weltrowska G, Coderre TJ. Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TIPP[Ψ]. Eur J Pharmacol 1995;286:105-108.
158. 2 opioid receptors. J Pharmacol Exp Ther 1997;280:1423-1431.
159. Kest B, Lee CE, McLemore GL, Inturrisi CE. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull 1996;39:185-188.
160. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, Pintar JE. Retention of supraspinal δ-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice. Neuron 1999;24:243-252.
161. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, O'Dowd BF. Oligomerization of μ- and δ-opioid receptors. Generation of novel functional properties. J Biol Chem 2000;275:26128-26135.
162. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of μ and δ opioid receptors: A role in opiate synergy. J Neurosci 2000;20:1-5.
163. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA. A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 2004;101:5135-5139.
164. 2[Ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morpine in rats. J Med Chem 1999;42:3520-3526.
165. Wells JL, Bartlett JL, Ananthan S, Bilsky EJ. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid μ-agonist/δ-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther 2001;297:597-605.
166. Ananthan S, Kezar HS, Carter RL, Saini SK, Rice KC, Wells JL, David P, Xu H, Dersch CM, Bilsky EJ. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. J Med Chem 1999;42:3527-3538.
167. Schiller PW, Weltrowska G, Berezowska I, Nguyen TM-D, Wilkes BC, Lemieux C, Chung NN. The TIPP opioid peptide family: Development of δ antagonists, δ agonists, and mixed μ agonist/δ antagonists. Biopolymers 1999;51:411-425.
168. 2[Ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem 1999;42:3520-3526.
169. Weltrowska G, Lemieux C, Chung NN, Schiller PW. A chimeric opioid peptide with mixed μ agonist/δ antagonist properties. J Pept Res 2004;63:63-68.
170. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci USA 2005;102:19208-19213.
171. Salvadori S, Trapella C, Fiorini S, Negri L, Lattanzi R, Bryant SD, Jinsmaa Y, Lazarus LH, Balboni G. A new opioid designed multiple ligand derived from the μ opioid agonist endomorphin-2 and the δ opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem 2007;15:6876-6881.
172. Hoffman O, Wiesenfeld-Hallin Z. The CCK-B receptor antagonist Cl988 reverses tolerance to morphine in rats. Neuroreport 1994;5:2565-2568.
173. Maldonado R, Valverde O, Ducos B, Blommaert AG, Fournie-Zaluski MC, Roques BP. Inhibition of morphine withdrawal by the association of RB101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134, 308. Br J Pharmacol 1995;114:1031-1039.
174. Powell KJ, Quirion R, Jhamandas K. Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Eur J Neurosci 2003;18:1572-1583.
175. Maldonado R, Girdlestone D, Roques BP. RP67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci Lett 1993;156:135-140.
176. Hruby VJ, Agenes RS, Davis P, Ma SW, Lee YS, Vanderah TW, Lai J, Porreca F. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci 2003;73:699-704.
177. Agnes RS, Lee YS, Davis P, Ma SW, Badghisi H, Porreca F, Lai J, Hruby VJ. Structure activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem 2006;49:2868-2875.
178. Maszczynska-Bonney I, Foran SE, Marchand JE, Lipkowski AW, Carr DB. Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties. Eur J Pharmacol 2004;488:91-99.
179. Allen RM, Dykstra LA. N-Methyl-D-aspartate receptor antagonists potentiate the antinociceptive effects of morphine in squirrel monkeys. J Pharmacol Exp Ther 2001;298:288-297.